TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01152580

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: 3mg p.o. at bedtime daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: lactose p.o. at bedtime daily
Study: NCT01688700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with paclitaxel and cisplatin
Description: Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy.
Study: NCT05027165

Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention
Study: NCT04654338

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR + HDR
Description: One SABR treatment + one HDR brachytherapy treatment
Study: NCT01542918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)
Study: NCT01057966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)
Description: Single, full strength dose tablet taken one time
Study: NCT03553810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto
Description: Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
Study: NCT04067466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber product
Description: Fiber product with inulin, maltodextrin, gum guar and plum powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Placebo product with maltodextrin and plum powder
Study: NCT00901693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-46383A Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-46383A Ophthalmic Solution Vehicle
Study: NCT04591522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy fecal bacteria liquid
Description: Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
Study: NCT02628210

Intervention type: OTHER
Group type: OTHER
Intervention: map3® Cellular Allogeneic Bone Graft
Description: Patients will receive map3® Cellular Allogeneic Bone Graft
Study: NCT01397838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-Bone
Description: 500 mg Capsules of Pro-Bone twice daily
Study: NCT01329367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein group
Description: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antioxidant group
Description: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control.
Study: NCT04026776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
Study: NCT01452750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Study: NCT02187991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: 40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: 40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
Study: NCT01835626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
Study: NCT01952327

Intervention type: DEVICE
Group type: OTHER
Intervention: The pleurapump system
Description: Implantation of the pleurapump system
Study: NCT00198562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Description: amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Description: amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
Study: NCT02576678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Study: NCT03545854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
Study: NCT04597268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous dexmedetomidine 1 mic/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine 1mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.05 mg/kg
Study: NCT01983410

Intervention type: BEHAVIORAL
Intervention: The risk assessment questionnaire

Intervention type: BEHAVIORAL
Intervention: The risk assessment questionnaire

Intervention type: BEHAVIORAL
Intervention: The risk assessment questionnaire

Intervention type: BEHAVIORAL
Intervention: The risk assessment questionnaire
Study: NCT04090879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
Description: 1) Altering the nicotine content of the tobacco research cigarette
Study: NCT01983410

Intervention type: BEHAVIORAL
Intervention: The risk assessment questionnaire
Study: NCT04090879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
Description: 1) Altering the nicotine content of the tobacco research cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
Description: 1) Altering the nicotine content of the tobacco research cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
Description: 1) Altering the nicotine content of the tobacco research cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
Study: NCT03076034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference Point Indentation
Description: The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference Point Indentation
Description: The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm.
Study: NCT01548040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab XP
Description: NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Quadriceps TENS
Description: on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
Study: NCT04565665

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Given IV
Study: NCT01959464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinone vaginal progesterone gel
Description: Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal gel
Description: Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
Study: NCT03763825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-AFTERc
Description: Structured 30-45 minute telephone discussion based on health psychology theory and CBT principles.
Study: NCT04245631

Intervention type: DIAGNOSTIC_TEST
Intervention: Recombinase aided amplification (RAA) assay
Description: We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
Study: NCT02404636

Intervention type: OTHER
Intervention: Interview
Description: Brief structured interview

Intervention type: OTHER
Intervention: Interview
Description: Brief structured interview
Study: NCT00122993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthful eating and food choices behavior change programs and changes in worksite food availability and prices
Description: Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity programs are offered at the intervention garages for an 18 month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment
Description: Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
Study: NCT01983410

Intervention type: OTHER
Intervention: Blood specimens

Intervention type: OTHER
Intervention: Blood specimens

Intervention type: OTHER
Intervention: Blood specimens

Intervention type: OTHER
Intervention: Blood specimens

Intervention type: OTHER
Intervention: Blood specimens

Intervention type: OTHER
Intervention: tumor tissue samples will be requested

Intervention type: OTHER
Intervention: tumor tissue samples will be requested

Intervention type: OTHER
Intervention: tumor tissue samples will be requested
Study: NCT02045238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Sodium Chloride 3% solution, previously prepared in 5 mL syringes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest X-Ray

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Chest X-Ray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory virus screening test
Description: Immunofluorescence analysis of nasal aspirate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory virus screening test
Description: Immunofluorescence analysis of nasal aspirate
Study: NCT02639130

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exendin [9-39]
Description: Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin [9-39]
Description: Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion as challenge agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo infusion as challenge agent
Study: NCT01538381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib for 2 weeks at a dose of 40 mg/day

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation
Study: NCT03905889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
Study: NCT04108468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Simponi
Study: NCT00737126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Administration of a daily tablet containing 5 mg of folic acid for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of an oral placebo pill